Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Intrinsic Value
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasa... [ Read More ]
The intrinsic value of one SNOA stock under the Base Case scenario is 3.622 USD. Compared to the current market price of 0.1663 USD, Sonoma Pharmaceuticals Inc is Undervalued by 95%.
Fundamental Analysis
Balance Sheet Decomposition
Sonoma Pharmaceuticals Inc
Current Assets | 12.5m |
Cash & Short-Term Investments | 2.4m |
Receivables | 2.9m |
Other Current Assets | 7.2m |
Non-Current Assets | 2.1m |
PP&E | 738k |
Other Non-Current Assets | 1.4m |
Current Liabilities | 3.1m |
Accounts Payable | 864k |
Accrued Liabilities | 2m |
Short-Term Debt | 44k |
Other Current Liabilities | 138k |
Non-Current Liabilities | 4.9m |
Other Non-Current Liabilities | 4.9m |
Earnings Waterfall
Sonoma Pharmaceuticals Inc
Revenue
|
12.3m
USD
|
Cost of Revenue
|
-7.5m
USD
|
Gross Profit
|
4.8m
USD
|
Operating Expenses
|
-9m
USD
|
Operating Income
|
-4.1m
USD
|
Other Expenses
|
-934k
USD
|
Net Income
|
-5.1m
USD
|
Free Cash Flow Analysis
Sonoma Pharmaceuticals Inc
What is Free Cash Flow?
SNOA Profitability Score
Profitability Due Diligence
Sonoma Pharmaceuticals Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Sonoma Pharmaceuticals Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
SNOA Solvency Score
Solvency Due Diligence
Sonoma Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Sonoma Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNOA Price Targets Summary
Sonoma Pharmaceuticals Inc
Ownership
SNOA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SNOA Price
Sonoma Pharmaceuticals Inc
Average Annual Return | -23.28% |
Standard Deviation of Annual Returns | 58.4% |
Max Drawdown | -99% |
Market Capitalization | 2.6m USD |
Shares Outstanding | 15 607 400 |
Percentage of Shares Shorted | 0.79% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.